Meta-analysis of the potential role of extracorporeal shockwave therapy in osteonecrosis of the femoral head

Table 1 The baseline characteristics of included studies

Study	Year	Study year	ONFH stage	Study style	Group	Number/hips	Gender (M/F)	Age (year)	Duration (month)
Wang CJ	2012	2001–2001	Stages I, II, early III	Non-RCT	ESWT	23/29	20/3	39.8 ± 12.1	25.2 ± 3.7
Wang CJ	2012	2001–2001	Stages I, II, early III	Non-RCT	Surgical group	25/28	22/3	39.9 ± 9.3	25.8 ± 4.6
Chen JM	2009	1999.7–2006.1	Stages I–III	Non-RCT	ESWT	17/17	14/3	42.9 ± 9.3	11.3 ± 3.4
Chen JM	2009	1999.7–2006.1	Stages I–IV	Non-RCT	THA	17/17	14/3	42.9 ± 9.3	14.7 ± 0.93
Zhang HJ	2015	2009.1–2012.12	Stages I–II	RCT	BMSC+ESWT	20/29	15/5	36.1 ± 6.2	24
Zhang HJ	2015	2009.1–2012.12	Stages I–II	RCT	BMSC	20/27	14/6	35.5 ± 5.7	24
Zhai L	2008	1998.1–2007.6	Stages I–III	Non-RCT	CD + ESWT	50/50	41/9	20.9(18–25)	6.4(3–18)
Zhai L	2008	1998.1–2007.6	Stages I–III	Non-RCT	CD	58/58	45/13	20.5(18–25)	7.3(3–20)

ESWT extracorporeal shock wave treatment, THA total hip arthroplasty, CD core decompression, M/F males/females, RCT randomized controlled trail, ONFH osteonecrosis of the femoral head, THA total hip, BMSC bone marrow stem cells

ISSN: 1749-799X